FLUCIL flucloxacillin (as sodium) 125mg/5mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

flucil flucloxacillin (as sodium) 125mg/5ml oral solution bottle

aspen pharmacare australia pty ltd - flucloxacillin sodium monohydrate, quantity: 27.2 mg/ml (equivalent: flucloxacillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: ammonium glycyrrhizinate; sodium benzoate; sucrose; saccharin sodium; disodium edetate; sodium citrate; erythrosine; flavour - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

FLUCIL flucloxacillin (as sodium) 250mg/5mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

flucil flucloxacillin (as sodium) 250mg/5ml oral solution bottle

aspen pharmacare australia pty ltd - flucloxacillin sodium monohydrate, quantity: 54.4 mg/ml (equivalent: flucloxacillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: erythrosine; sodium citrate; sodium benzoate; sucrose; ammonium glycyrrhizinate; disodium edetate; saccharin sodium; flavour - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE tablet United States - English - NLM (National Library of Medicine)

diphenoxylate hydrochloride and atropine sulfate tablet

aphena pharma solutions - tennessee, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride 2.5 mg - diphenoxylate hydrochloride is effective as adjunctive therapy in the management of diarrhea. diphenoxylate hydrochloride is contraindicated in patients with: - known hypersensitivity to diphenoxylate or atropine. - obstructive jaundice. - diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. diphenoxylate hydrochloride is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE tablet United States - English - NLM (National Library of Medicine)

diphenoxylate hydrochloride and atropine sulfate tablet

greenstone llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride 2.5 mg - diphenoxylate hydrochloride and atropine sulfate is indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate is contraindicated in: diphenoxylate hydrochloride and atropine sulfate is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets

Trihexyphenidyl 2mg Tablets Malta - English - Medicines Authority

trihexyphenidyl 2mg tablets

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - trihexyphenidyl hydrochloride - tablet - trihexyphenidyl hydrochloride 2 mg - anti-parkinson drugs

Trihexyphenidyl 5mg Tablets Malta - English - Medicines Authority

trihexyphenidyl 5mg tablets

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - trihexyphenidyl hydrochloride - tablet - trihexyphenidyl hydrochloride 5 mg - anti-parkinson drugs

LANOXIN PAEDIATRIC Elixir Australia - English - Department of Health (Therapeutic Goods Administration)

lanoxin paediatric elixir

aspen pharma pty ltd - digoxin, quantity: 50 microgram/ml - oral liquid - excipient ingredients: methyl hydroxybenzoate; dibasic sodium phosphate heptahydrate; sucrose; citric acid; ethanol; propylene glycol; quinoline yellow; purified water; flavour - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

MAXAMOX amoxicillin trihydrate 500mg/5mLpowder for oral suspension bottle Australia - English - Department of Health (Therapeutic Goods Administration)

maxamox amoxicillin trihydrate 500mg/5mlpowder for oral suspension bottle

sandoz pty ltd - amoxicillin trihydrate, quantity: 114.82 mg/ml (equivalent: amoxicillin, qty 100 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

AMOXYCILLIN SANDOZ amoxicillin trihydrate 125mg/5mL powder for oral suspension bottle Australia - English - Department of Health (Therapeutic Goods Administration)

amoxycillin sandoz amoxicillin trihydrate 125mg/5ml powder for oral suspension bottle

sandoz pty ltd - amoxicillin trihydrate, quantity: 28.77 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

AMOXYCILLIN SANDOZ amoxicillin trihydrate 250mg/5mL powder for oral suspension bottle Australia - English - Department of Health (Therapeutic Goods Administration)

amoxycillin sandoz amoxicillin trihydrate 250mg/5ml powder for oral suspension bottle

sandoz pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.